- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.11.25 | HEXIMA LIMITED: AGM - Results of Meeting | - | ASX | ||
| 27.11.25 | HEXIMA LIMITED: AGM - Chair's Address - The Path Forward | 1 | ASX | ||
| 31.10.25 | HEXIMA LIMITED: Business Activity Statement & Appendix 4C - Sep-2025 Qtr | - | ASX | ||
| 24.10.25 | HEXIMA LIMITED: Annual General Meeting & Proxy Form | - | ASX | ||
| HEXIMA Aktie jetzt für 0€ handeln | |||||
| 15.10.25 | HEXIMA LIMITED: Long Term Suspended Entities | - | ASX | ||
| 19.09.25 | HEXIMA LIMITED: Annual General Meeting & Director Nomination | - | ASX | ||
| 29.08.25 | HEXIMA LIMITED: 2025 Annual Report | - | ASX | ||
| 29.08.25 | HEXIMA LIMITED: Appendix 4G | - | ASX | ||
| 29.08.25 | HEXIMA LIMITED: Appendix 4E | - | ASX | ||
| 31.07.25 | HEXIMA LIMITED: Business Activity Statement & Appendix 4C - Jun-2025 Qtr | - | ASX |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOME | 22,850 | 0,00 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| ERASCA | 9,560 | 0,00 % | Erasca, Inc.: Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones | Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,270 | 0,00 % | Summit Therapeutics: H.C. Wainwright bestätigt "Buy"-Rating und Kursziel von 40 US-Dollar | ||
| KYMERA THERAPEUTICS | 71,12 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs | KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 297,74 | -0,24 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy | BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,640 | 0,00 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| NUVALENT | 106,16 | 0,00 % | Nuvalent, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 17,500 | 0,00 % | ADMA Biologics, Inc. (ADMA): A Bull Case Theory | ||
| DISC MEDICINE | 71,04 | -7,84 % | Disc Medicine Inc: Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer | WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,240 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| VERA THERAPEUTICS | 46,280 | 0,00 % | Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept | ||
| ARCELLX | 68,32 | -2,20 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target | ||
| TARSUS PHARMACEUTICALS | 73,65 | -2,18 % | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | ||
| ALUMIS | 24,170 | -0,70 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 31,380 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen |
HEXIMA LIMITED gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEXIMA LIMITED finden Sie auf Wallstreet Online.